Capstan Therapeutics / AbbVie
AbbVie completed its Capstan acquisition in August 2025. CPTX2309 uses targeted LNP in vivo CAR-T technology; the sponsor lists NCT06917742 as a recruiting Phase 1 study in healthy volunteers, rheumatoid arthritis, and SLE. Registration does not establish efficacy.
Corporate information
- Company entity
- Capstan Therapeutics / AbbVie
- Headquarters / principal office
- No verified public location identified
- Founded
- 2021 ↗
- Ownership / capital status
- AcquiredAcquired by AbbVie; historical Series B ↗
- Official corporate reference
- https://www.abbvie.com/capstan-therapeutics.html ↗ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2024-03-20 · Series B (before acquisition) · $175 million ↗
Historical equity financing confirmed by the investor. The 2025 AbbVie acquisition is not a financing round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
AbbVie completed its Capstan acquisition in August 2025. CPTX2309 uses targeted LNP in vivo CAR-T technology; the sponsor lists NCT06917742 as a recruiting Phase 1 study in healthy volunteers, rheumatoid arthritis, and SLE. Registration does not establish efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Capstan Therapeutics is now a part of AbbVie | AbbVie
- AbbVie completes Capstan acquisition
- CPTX2309-01-01 / NCT06917742 — AbbVie trial registry
- Penn — Capstan launch and seed/Series A financing